What Is SPRAVATO?
SPRAVATO™ is the only NMDA receptor antagonist approved in conjunction with an oral antidepressant for treatment resistant depression. It contains esketamine, a schedule III-controlled substance, related to ketamine, an anesthetic that also has been studied to help in the treatment of depression.
What Is Treatment Resistant Depression?
The depression is considered resistant to treatment after failing to respond to two trials of antidepressants. About 30 percent of the patients suffering from depression do not respond to the standard treatments. Ketamine and esketamine are similar but not identical. They are enantiomers, meaning that their chemical structures are mirror images of each other. Both can be used as anesthetics but esketamine has more potency acting on the brain receptors.
Research On Ketamine And Esketamine
Ketamine IV has been extensively studied and there are numerous clinics throughout the US offering ketamine IV as a treatment for depression even though it does not have an FDA approval. The administration is done over a period of 40 minutes, at a subanesthetic dose.
Esketamine can be administered intranasally, it is FDA approved, has less potential for dissociation and hopefully will be covered soon by the insurance carriers.
Administration Of Esketamine And Possible Side Effects
Because esketamine, like ketamine has abuse potential, there are very strict rules related to its administration. It must be done in the doctor’s office, under direct supervision, followed by a period of two hours of observation. Following the administration, dissociative episodes can happen therefore the patient should not engage in driving or operating any machinery. The most common side effects are feeling dissociated form one’s body, dizziness, nausea, sedation, vertigo, anxiety, increased blood pressure, vomiting and feeling drunk.
If you’d like to learn more about SPRAVATO for treatment resistant depression and esketamine- call us to set up at appointment at 713-426-3100. If you’d like a brochure click here.